Sangamo Therapeutics receives FDA Fast Track Designation for ST-503 treatment.

Sangamo Therapeutics announced that the FDA has granted Fast Track Designation to ST-503, an investigational epigenetic regulator, for the treatment of intractable pain due to small fiber neuropathy. The designation aims to facilitate the development and review of new therapeutics, providing more frequent interactions with the FDA and potential eligibility for Accelerated Approval and Priority Review. ST-503 targets a type of chronic neuropathic pain with limited effective treatments.